Uniqure NV News - UQ1

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease LEXINGTON...

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s...

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with...

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of...

uniQure to Participate in Upcoming Industry Conferences in November

uniQure to Participate in Upcoming Industry Conferences in November LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE...

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress ~ Completed 78-week follow-up for hemophilia B...

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors Biotech Executive Brings Extensive Experience Developing...

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) Oral Presentation to Highlight...

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in October LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE...

uniQure to Participate in Multiple Upcoming Industry Conferences in September

uniQure to Participate in Multiple Upcoming Industry Conferences in September LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE...

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II...

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress ~ Expanded gene therapy pipeline with four new...

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress LEXINGTON, Mass. and...

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Pati...

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with...

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) ~ Expands uniQure’s...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1)

Empower your portfolio: Real-time discussions and actionable trading ideas.

UQ1 News

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure to Participate in Upcoming Industry Conferences in November

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in September

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Pati...

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

UQ1 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1) News

Uniqure NV (UQ1)

Empower your portfolio: Real-time discussions and actionable trading ideas.

UQ1 News

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure to Participate in Upcoming Industry Conferences in November

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

uniQure to Participate in Multiple Upcoming Industry Conferences in October

uniQure to Participate in Multiple Upcoming Industry Conferences in September

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Pati...

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)

UQ1 Discussion

Your Recent History